期刊文献+

沙培林联合卡铂治疗晚期肺癌恶性胸水的临床观察

Clinic Study on Treatment Malignant Thotacic Hydrops by Carboplatin Combined with Group A Streptococcusin Jection
暂未订购
导出
摘要 目的探讨沙培林联合卡铂治疗恶性胸腔积液的临床疗效。方法将88例恶性胸水患者随机分为治疗组44例和对照组44例,治疗组采用沙培林联合卡铂胸腔注射,对照组单纯用卡铂治疗。结果治疗组控制胸水的有效率为90.9%,对照组为61%,两者比较差异有显著性(P<0.01)。治疗组副作用为发热、胸痛、骨髓抑制和消化道反应,两组比较无显著性差异(P>005)。结论沙培林联合卡铂胸腔注射能有效治疗恶性胸水,且简单易行,较单药卡铂疗效好。 Objective To evaluate the effect of carboplatin combined streptococcus for injection saintra thoracic instillation on lung cancer accompanied severe hydrothorax. Methods 88 patients with malignant thotacic hydrops in lung cancer were divided into two groups randomly. Then given streptococcus and carboplatin for injection intrathoracic instillation for treatment groups, only carboplatin for injection intrathoracic instillation for comparison groups. Results Total effct rate for carbopolatin combined with A streptococcus for injection is 90.9%. While that for carboplatin is 61%. There is so obvious difference between the two groups(P〈0.01). and the bad response of treatment group is lower than that of comparison group, but There is no obvious difference between the two groups(P〉0.05). The main side effects were fever, chest ache, arrest of bone marrow, digestive tract reaction. Conclusion Carboplatin combined streptococcus for injections aintrathoracic instillation on lung cancer accompanied severe hydrothorax is simple and effective, and it is better than that only carboplatin.
作者 卢忠 黄国森
出处 《国际医药卫生导报》 2006年第19期65-67,共3页 International Medicine and Health Guidance News
关键词 肺癌 恶性胸水 沙培林 卡铂 胸腔注射 Lung cancer Hydrothorax Carboplatin Group A streptococcus Saintrathoracic instillation
  • 相关文献

参考文献5

二级参考文献20

  • 1谢海燕.S311抗癌菌苗治疗恶性胸水疗效分析[J].海军医学杂志,2000,21(2):123-124. 被引量:1
  • 2赵家美 廖美琳 等.沙培林对癌性胸腔积液的疗效观察[J].中华结核和呼吸杂志,1994,(17):161-161.
  • 3[1]Mizutani Y, Nio Y, Yoshida O. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes [J]. Cancer, 1997;69(6):2999-3007.
  • 4Sahn SA. Management of malignant pleural effusions[J ]. Monaldi Arch Chest Dis,2001,56(5):394- 399.
  • 5Parulekar W,Di Primio G, Matzinger F, et al. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions[J]. Chest,2001,120(1) : 19 - 25.
  • 6Brant A,Eaton T. Serious complications with talc slurry pleurodesis[ J ]. Respirology,2001,6(3) : 181 - 185.
  • 7Cardillo O, Facciolo F, Carbone L,et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions[J]. Eur J Cardiothorac Surg,2002,21(2) :302 - 305.
  • 8Furedi A,Kecskes L,Geher P,et al. Video-assisted thoraeoseopic pleurodesis for malignant pleural effusions [J]. Aeta Chir Hung, 1999,38(2) : 155 - 157.
  • 9Schulze M,Boehle AS,Kurdow R,et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients [J ]. Ann Thorac Surg, 2001,71(6) -1809 - 1812.
  • 10Genc O,Petrou M,Ladas G, et al. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions [ J ]. Eur J Cardiothorac Surg,2000,18(2) : 143 - 146.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部